Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Short Interest Down 90.0% in June

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the target of a large decrease in short interest in June. As of June 15th, there was short interest totaling 4,540 shares, a decrease of 90.0% from the May 31st total of 45,360 shares. Based on an average daily volume of 92,782 shares, the days-to-cover ratio is presently 0.0 days. Approximately 0.1% of the shares of the company are short sold.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut shares of Sonoma Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, April 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Sonoma Pharmaceuticals presently has an average rating of “Sell”.

Institutional Trading of Sonoma Pharmaceuticals

An institutional investor recently bought a new position in Sonoma Pharmaceuticals stock. McKinley Carter Wealth Services Inc. purchased a new stake in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 11,193 shares of the company’s stock, valued at approximately $41,000. McKinley Carter Wealth Services Inc. owned approximately 0.66% of Sonoma Pharmaceuticals at the end of the most recent quarter. Institutional investors and hedge funds own 1.95% of the company’s stock.

Sonoma Pharmaceuticals Stock Performance

NASDAQ SNOA traded down $0.02 on Friday, reaching $1.12. 35,994 shares of the company’s stock traded hands, compared to its average volume of 143,876. The firm has a market cap of $5.36 million, a price-to-earnings ratio of -0.59 and a beta of 1.29. The stock has a 50 day moving average price of $1.26 and a 200-day moving average price of $2.38. Sonoma Pharmaceuticals has a fifty-two week low of $0.85 and a fifty-two week high of $6.92.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last announced its quarterly earnings results on Tuesday, June 16th. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.09). The company had revenue of $5.56 million for the quarter, compared to analyst estimates of $5.57 million. Sonoma Pharmaceuticals had a negative return on equity of 43.95% and a negative net margin of 16.26%.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.